- Home
- MTEK vs CLRB Comparison
MTEK vs CLRB Comparison
Compare MTEK & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTEK | CLRB |
|---|---|---|
| Founded | 2008 | 2002 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 12.8M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | MTEK | CLRB |
|---|---|---|
| Price | $1.67 | $3.51 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 88.0K | ★ 130.0K |
| Earning Date | 09-26-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,375,716.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.03 | $2.45 |
| 52 Week High | $4.27 | $20.60 |
Technical Indicators
Market Signals| Indicator | MTEK | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 64.42 | 50.98 |
| Support Level | $1.51 | $3.33 |
| Resistance Level | $1.89 | $3.98 |
| Average True Range (ATR) | 0.14 | 0.30 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 65.74 | 42.31 |
Price Performance
Historical ComparisonAbout MTEK Maris-Tech Ltd.
Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.